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Many organs rely on undifferentiated stem and
progenitor cells for tissue regeneration. Whether
differentiated cells themselves can contribute to
cell replacement and tissue regeneration is a contro-
versial question. Here, we show that differentiated
heart muscle cells, cardiomyocytes, can be induced
to proliferate and regenerate. We identify an under-
lying molecular mechanism for controlling this
process that involves the growth factor neuregulin1
(NRG1) and its tyrosine kinase receptor, ErbB4.
NRG1 induces mononucleated, but not binucleated,
cardiomyocytes to divide. In vivo, genetic inactiva-
tion of ErbB4 reduces cardiomyocyte proliferation,
whereas increasing ErbB4 expression enhances it.
Injecting NRG1 in adult mice induces cardiomyocyte
cell-cycle activity and promotes myocardial regener-
ation, leading to improved function after myocardial
infarction. Undifferentiated progenitor cells did not
contribute to NRG1-induced cardiomyocyte prolifer-
ation. Thus, increasing the activity of the NRG1/
ErbB4 signaling pathway may provide a molecular
strategy to promote myocardial regeneration.
INTRODUCTION
Specific organ functions rely on differentiated cells. How differ-
entiated cells are replaced is a fundamental question in biology
with important implications for regenerative medicine. Although
progenitor cells are important for regeneration in many organs,
differentiated cells may also contribute by reverting to a prolifer-
ative state. Examples of differentiated cells contributing to tissue
renewal are insulin-producing b cells in the mouse pancreas (Dor
et al., 2004), heart muscle cells in regenerating zebrafish hearts
(Poss et al., 2002), tracheal cells in Drosophila larvae during
metamorphosis (Guha et al., 2008; Weaver and Krasnow,
2008), and Arabidopsis root cells after amputation of the stem
cell niche (Sena et al., 2009).
If heart muscle cells, cardiomyocytes, can be induced to
proliferate, it might be possible to regenerate heart muscleafter myocardial infarction. Cardiomyocytes proliferate during
prenatal development (Pasumarthi and Field, 2002). Soon after
birth, however, cardiomyocytes become binucleated and with-
draw from the cell cycle, giving rise to the notion that adult car-
diomyocytes are incapable of proliferating; that is, they are termi-
nally differentiated (Pasumarthi and Field, 2002). Specifically,
cardiomyocytes in the adult mammalian heart are thought to
be incapable of performing cytokinesis, the ultimate step of
the mitotic cell cycle (Ahuja et al., 2007; Pasumarthi and Field,
2002).
Recent results challenge the paradigm that the adult heart is
exclusively a terminally differentiated organ (Bergmann et al.,
2009). Although cardiac regeneration has been studied for
more than a century, little progress has been made in character-
izing the mechanisms that control cell-cycle reentry of differenti-
ated cardiomyocytes. Rather than attempt to answer the ques-
tion about whether adult progenitor cells can give rise to new
cardiomyocytes, we tested an alternative possibility—that cardi-
omyocytes have proliferative potential. We hypothesized that
some differentiated cardiomyocytes are quiescent; that is, they
do not proliferate under resting conditions but may proliferate
in response to extracellular mitogens. To test this hypothesis,
we used extracellular factors, such as fibroblast growth factor1
(FGF1), periostin, and neuregulin1 (NRG1), that activate recep-
tors involved in cardiomyocyte proliferation during prenatal
development (Pasumarthi and Field, 2002). NRG1 is an agonist
for receptor tyrosine kinases of the epidermal growth factor
receptor family, consisting of ErbB1, 2, 3, and 4 (Fuller et al.,
2008). Binding of NRG1 to ErbB4 increases its kinase activity
and leads to heterodimerization with ErbB2 or homodimerization
with ErbB4 and stimulation of intracellular signal transduction
pathways. Mice with germline knock-out of the NRG1, ErbB2,
or ErbB4 genes have thinner myocardium and die at midgesta-
tion, indicating that each of these genes is independently
required for fetal cardiomyocyte generation (Gassmann et al.,
1995; Lee et al., 1995; Meyer and Birchmeier, 1995).
The NRG1 receptor subunits ErbB2 and ErbB4 are also
expressed in differentiated cardiomyocytes (Fuller et al., 2008).
It became apparent that the NRG1/ErbB2/ErbB4 signaling
complex is functionally active in differentiated cardiomyocytes
when women receiving breast cancer treatment with the
ErbB2-blocking antibody, Herceptin, developed cardiomyop-
athy (Keefe, 2002). In vitro studies have suggested that theCell 138, 257–270, July 24, 2009 ª2009 Elsevier Inc. 257
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Figure 1. NRG1 Induces Cell-Cycle Reentry and Division of Differentiated Cardiomyocytes In Vitro
Primary adult rat ventricular cardiomyocytes were stimulated and labeled with BrdU for the last 3 days, and DNA synthesis was determined by immunofluores-
cence microscopy after 9 days.
(A) NRG1 (100 ng/ml), fibroblast growth factor 1 (FGF1, 100 ng/ml), and periostin (500 ng/ml) induce cardiomyocyte DNA synthesis, while epidermal growth
factor (EGF), heparin-binding epidermal growth factor (HB-EGF), or platelet-derived growth factor BB (PDGF, 100 ng/ml each) do not. Results were normalized
to NRG1 = 100%.
(B) NRG1-stimulated cardiomyocyte DNA synthesis was concentration dependent.
(C) NRG1-stimulated (125 pM) cardiomyocyte DNA synthesis inhibited with increasing concentrations of an antibody against ErbB2.
(D) Functional inhibition of PI3K with PTEN attenuates NRG1-stimulated DNA synthesis in cardiomyocytes.
258 Cell 138, 257–270, July 24, 2009 ª2009 Elsevier Inc.
NRG1/ErbB2/ErbB4 complex controls cardiomyocyte survival
and myofibril disarray. However, these effects were not ob-
served in knock-out mice in vivo (Fuller et al., 2008), indicating
that ErbB2 and ErbB4 may act through other cellular mecha-
nisms.
In this study, we show that NRG1 can induce mononucleated
cardiomyocytes to proliferate. We reveal the underlying mecha-
nisms and present a model of cardiomyocyte proliferation.
Finally, we demonstrate that NRG1-induced cardiomyocyte pro-
liferation promotes myocardial regeneration following myocar-
dial injury.
RESULTS
NRG1 Stimulates Cell-Cycle Reentry and Division
of Differentiated Cardiomyocytes
To identify factors that promote myocardial regeneration, we
screened extracellular factors for their ability to induce DNA
synthesis in primary adult rat ventricular cardiomyocytes. Three
extracellular factors induced cardiomyocyte cell-cycle reentry.
Two have been previously identified: fibroblast growth factor1
(FGF1; Engel et al., 2005) and periostin (Kuhn et al., 2007). The
novel factor was the epidermal growth factor-like domain of
NRG1b (Figure 1A; see also Figure S1 available online). NRG1
induced concentration-dependent DNA synthesis, which best
fit a sigmoidal function, suggesting a receptor-mediated process
(Figure 1B). The half-maximal stimulation EC50 was 40 ± 3 pM
(n = 3; Figure 1B), indicating a high-affinity interaction with the
receptor. In cardiomyocytes, NRG1 binds to ErbB4, which leads
to formation and activation of ErbB2/ErbB4 hetero- or ErbB4/
ErbB4 homodimers (Fuller et al., 2008). To determine whether
ErbB2 is required for cardiomyocyte cell-cycle reentry, we
added a fixed concentration of NRG1 (125 pM) and increasing
concentrations of ErbB2-blocking antibody. The anti-ErbB2 anti-
body inhibited NRG1-stimulated DNA synthesis with an IC50 of
21 ± 4 pM (n = 3; Figure 1C), suggesting that ErbB2 is required
for the NRG1 effect.
The phosphatidylinositol-3-OH kinase (PI3-kinase) pathway is
required for cardiomyocyte cell-cycle reentry induced by FGF
and periostin (Kuhn et al., 2007). Using functional inhibition
with PTEN, we demonstrate that NRG1 also required the PI3-
kinase pathway (Figure 1D), thus suggesting that different extra-
cellular factors induce cardiomyocyte proliferation by activating
pathways that converge at PI3-kinase. In summary, the ternary
complex of NRG1, ErbB2, and ErbB4 enhances cardiomyocyte
cell-cycle activity in a PI3-kinase-dependent mechanism.
To determine whether NRG1 induces differentiated cardio-
myocytes to reenter the cell cycle, we ascertained the phenotypeof individual cardiomyocytes before stimulation. NRG1 induced
DNA synthesis in 0.4% ± 0.1% of cardiomyocytes over a period
of 3 days (Figure 1E). We detected cytokinesis by visualizing
aurora B kinase, a required component of the contractile ring
at the site of cytoplasmic separation (Tatsuka et al., 1998). In
NRG1-stimulated samples, 0.05% ± 0.01% of cardiomyocytes
were in the process of cytokinesis (Figure 1F). Because most
differentiated cardiomyocytes are multinucleated, it is possible
that they undergo cytokinesis without prior DNA synthesis and
karyokinesis. We therefore analyzed the time course of NRG1-
induced cardiomyocyte DNA synthesis and cytokinesis and
found that DNA synthesis preceded cytokinesis (Figure 1G).
In addition, cardiomyocytes in cytokinesis had BrdU-positive
nuclei, indicating that they underwent DNA synthesis prior to
cytokinesis (Figure 1H).
To determine whether differentiated cardiomyocytes complete
cytokinesis, we used video microscopy. NRG1 induced 3% ±
1.4% of differentiated cardiomyocytes to perform karyokinesis
and 0.6% ± 0.3% to perform cytokinesis (n = 716). All of the
observed cycling cardiomyocytes were viable for the entire dura-
tion of observation (75.4 ± 17.7 hr; range, 15–163 hr; n = 25). In
summary, these data indicate that NRG1 induces differentiated
cardiomyocytes to reenter the cell cycle from S phase and to
complete cytokinesis in vitro.
Mononucleated Cardiomyocytes Have
Proliferative Potential
Using video microscopy, we prospectively determined the prolif-
erative potential of mono- and binucleated cardiomyocytes
(Figure 1I; Movies S1 and S2). We found that NRG1 induced
32.6% ± 4.8% (n = 88) of mononucleated cardiomyocytes to
perform karyokinesis. In contrast, only 1% ± 0.5% of all binucle-
ated cardiomyocytes (n = 628) performed karyokinesis (p = 0.02,
t test). Moreover, 45.8% ± 20.8% (n = 11) of mononucleated
cardiomyocytes that entered cytokinesis also completed cytoki-
nesis with abscission; the rest became binucleated. In total,
0.6% ± 0.3% of all cardiomyocytes divided, all of which were
mononucleated.
ErbB4 Controls Postnatal Cardiomyocyte
Proliferation In Vivo
To determine whether the NRG1/ErbB2/ErbB4 complex controls
cardiomyocyte proliferation in postnatal hearts in vivo, we dis-
rupted the complex by genetically inactivating the ErbB4 gene.
We treated a-MHC-MerCreMer+/+; ErbB4F/F mice (test) and
a-MHC-MerCreMer+/+; ErbB4Wt/F mice (control littermates)
with tamoxifen. Following ErbB4 inactivation on postnatal days
2–4, we analyzed the effect on postnatal day 19. Cardiomyocyte(E and F) Optical fate mapping of individual cardiomyocytes. Representative examples of corresponding phase contrast images before stimulation and immu-
nofluorescent images after 9 days of stimulation with NRG1 and labeling with BrdU for the final 3 days. Graphs show portion of cardiomyocytes performing DNA
synthesis over a period of 3 days (E) and that were in cytokinesis on day 9 (F).
(G) Cardiomyocyte DNA synthesis precedes cytokinesis.
(H) BrdU-labeled cardiomyocyte in cytokinesis, indicating progression through the complete cell cycle.
(I) Mononucleated cardiomyocyte undergoing karyokinesis and cytokinesis. Histone 2B-GFP was expressed under control of the troponin T promoter (green) to
visualize cardiomyocyte chromatin. Images were captured every 1 hr. Selected images are shown, as indicated at the bottom. The complete movie is provided in
Movie S1. Arrowheads indicate cleavage furrow at 141 hr and 146 hr. Scale bars, 50 mm. No stim., no stimulation. Data are means ± standard error of the mean
(SEM) from at least three experiments. Statistical significance was determined by ANOVA (A and D) and t test (E and F).
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Figure 2. ErbB4 Controls Postnatal Cardiomyocyte Proliferation In Vivo
(A–C) Experiments were performed in a-MHC-MerCreMer+/+; ErbB4F/F (test group) and in a-MHC-MerCreMer+/+; ErbB4Wt/F (control group) mice. (A) Inactivation
of ErbB4 does not affect portion of mono- and multinucleated cardiomyocytes. (B and C) Inactivation of ErbB4 abolishes postnatal cardiomyocyte cell-cycle
activity (B) and disrupts cardiomyocyte proliferation (C).
(D–H) Experiments were performed in a-MHC-ErbB4 mice (test group) and wild-type littermates (control group).
(D) Transgenic expression of ErbB4 under control of the a-MHC promoter does not change the portion of mono- and multinucleated cardiomyocytes.
(E) Overexpressing ErbB4 in differentiated cardiomyocytes increases cell-cycle activity of mononucleated cardiomyocytes. Examples of BrdU-positive mono-
nucleated differentiated cardiomyocyte and BrdU-negative binucleated cardiomyocyte and quantification are shown.
(F) Overexpressing ErbB4 has no effect on cardiomyocyte apoptosis. Positive control is 1 week after myocardial infarction, from Figure 7B.
(G and H) ErbB4-induced cardiomyocyte cell-cycle activity results in more (G) and smaller (H) cardiomyocytes. Scale bars 25 mm. Significance tested by ANOVA
(A, B, and E) and t test (C, F–H). Results are means ± SEM from more than eight different hearts per experiment.differentiation was not affected, as demonstrated by two obser-
vations: the formation of bi- and multinucleated cardiomyocytes
was not altered (Figure 2A), and cardiomyocytes from test and
control mice had indistinguishable morphology (Figure 2B). To
determine whether ErbB4 is required for postnatal cardiomyo-
cyte cell cycling, we quantified cardiomyocytes that incorpo-
rated BrdU (Figure 2B). After 5 injections of BrdU on postnatal
days 16–18, test mice had no detectable cardiomyocyte BrdU
uptake, whereas control mice had 5% ± 2.9% (n = 4) BrdU-posi-260 Cell 138, 257–270, July 24, 2009 ª2009 Elsevier Inc.tive mononucleated cardiomyocytes (p < 0.01, Figure 2B).
Neither a-MHC-MerCreMer+/+; ErbB4F/F mice in the absence
of tamoxifen (Figure 2B) nor a-MHC-MerCreMer+/+;ErbB4Wt/Wt
mice treated with tamoxifen (Figure S2D) had reduced NRG1-
induced cardiomyocyte cycling, thus confirming that inactivation
of both ErbB4 alleles was required. To test whether the decrease
in cell-cycle activity in ErbB4-inactivated mice would result in
lower cardiomyocyte numbers, we determined the volume
density of cardiomyocyte nuclei, which was 20% lower
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Figure 3. NRG1 Induces Cycling of Differentiated Cardiomyocytes In Vivo in an ErbB4-Dependent Mechanism
(A) Experimental design. Vertical arrowheads indicate daily NRG1 injections.
(B) ErbB4 controls NRG1-induced cardiomyocyte cell cycling.
(C) Proportions of mono-, bi-, and multinucleated cardiomyocytes are not affected by modulating NRG1/ErbB4 signaling.
(D and E) NRG1 induces cardiomyocyte karyokinesis (D) and cytokinesis (E). Aurora B-kinase-positive midbody is shown in a series of XZ reconstructions. Scale
bar, 25 mm. Results are means ± SEM from at least five animals per experiment.(Figure 2C; Table S1). Taken together, ErbB4 is required for
normal postnatal cardiomyocyte proliferation.
To determine whether ErbB4 is sufficient to increase cycling
of differentiated cardiomyocytes, we overexpressed ErbB4
under control of the a-MHC promoter (a-MHC-ErbB4; Tidcombe
et al., 2003), which did not alter the percentage of mono- and
multinucleated cardiomyocytes, indicating that ErbB4 did not
affect the normal postnatal formation of multinucleated cardio-
myocytes (Figure 2D). To analyze cardiomyocyte cell cycling,
we quantified cardiomyocyte BrdU uptake. Control mice at 14
days of age had BrdU uptake in 7.2% ± 5.3% (n = 6) of mononu-
cleated cardiomyocytes (Figure 2E). In contrast, a-MHC-ErbB4
transgenic mice had BrdU uptake in 22.6% ± 8.5% (n = 5) of
mononucleated cardiomyocytes, a 3-fold increase (p < 0.05).
ErbB4-transgenesis did not affect cardiomyocyte apoptosis
(Figure 2F). The increased cell-cycle activity in ErbB4-transgenic
hearts resulted in a higher volume density of cardiomyocyte
nuclei (Figure 2G), consistent with smaller cardiomyocytes
(Figure 2H) of normal proportions (Figure S3). In the presence
of identical myocardial mass and volume and identical propor-
tions of mono- and multinucleated cardiomyocytes (Tables S2–
S4; Figure 2D), this indicates that a-MHC-ErbB4 transgenic
hearts have more cardiomyocytes that are smaller. In summary,
these results demonstrate that ErbB4 is sufficient to increase
cardiomyocyte proliferation in vivo.NRG1 Induces Cardiomyocyte Cell-Cycle Reentry,
Karyokinesis, and Cytokinesis In Vivo
Cardiomyocytes in adult mammalian hearts do not proliferate
under baseline conditions (Pasumarthi and Field, 2002). To deter-
mine whether stimulating the NRG1/ErbB4 signaling pathway
induces cardiomyocyte cell-cycle reentry in vivo, we injected
recombinant NRG1 in 3-month-old mice, labeled with BrdU in
the drinking water for 9 days, and then quantified cardiomyocyte
cell-cycle activity (Figure 3A). In control mice, we did not detect
cycling cardiomyocytes (Figure 3B), in accordance with pub-
lished results (Soonpaa and Field, 1998). In contrast, in mice
injected with recombinant NRG1, 14.3% ± 6.5% of mononucle-
ated and 3% ± 1.2% of multinucleated cardiomyocytes were
BrdU positive (n = 3; p < 0.001; Figure 3B). Thus, NRG1 induces
differentiated cardiomyocytes to leave proliferative quiescence.
We next determined whether the NRG1-induced cardiomyo-
cyte cell-cycle reentry was mediated by ErbB4. Injecting NRG1
into ErbB4-transgenes did not increase cardiomyocyte cycling
above the level of injecting NRG1 into littermate controls, sug-
gesting that ErbB4 expression levels were not limiting cardio-
myocyte cell-cycle reentry (Figure 3B). We then inactivated
ErbB4, which resulted in a marked decrease of NRG1-induced
cardiomyocyte DNA synthesis, indicating that ErbB4 was
required for NRG1-induced cardiomyocyte cell-cycle reentry
(Figure 3B). Importantly, the proportions of mono- andCell 138, 257–270, July 24, 2009 ª2009 Elsevier Inc. 261
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Figure 4. NRG1 Induces Proliferation of Differentiated Cardiomyocytes In Vivo
(A) Experimental design for genetic fate map using a-MHC-MerCreMer+/+; Rosa26Rmice+/. Vertical arrowheads indicate injections of tamoxifen (Tam) to induce
permanent genetic labeling and NRG1 injections.
(B and C) NRG1-induced DNA synthesis (B) and karyokinesis (C) originate from differentiated cardiomyocytes, evident by X-gal staining.
(D and E) Representative examples of cardiomyocyte clusters after 9 NRG1 injections (D) and quantification (E).
(F) Cardiomyocyte proliferation in adult mice (3 months) was induced with 9 daily injections of NRG1. Repeated transition through the S phase of the cell cycle was
detected by successively labeling with the thymidine analogs chlorodeoxyuridine (CldU) and iododeoxyridine (IdU).
(G) Example of a binucleated cardiomyocyte after one S phase transition.
(H and I) Examples of mononucleated (H) and binucleated (I) cardiomyocytes after two rounds of S phase transition. An isolated nucleus is attached to the outside
of the cardiomyocyte in (I).
(J) Diagram of portion of cardiomyocytes by frequency of cell-cycle transitions and number of nuclei.
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multinucleated cardiomyocytes were not different between the
experimental groups (Figure 3C). We determined whether
NRG1 induced cardiomyocyte karyokinesis (Figure 3D). In
NRG1-injected animals, 0.4% ± 0.1% of mononucleated cardio-
myocytes were in the process of karyokinesis, but none in
controls. We then quantified cardiomyocyte cytokinesis, the
terminal phase of the cell cycle (Figure 3E). In NRG1-injected
animals, 0.3% ± 0.1% of mononucleated cardiomyocytes were
in the process of cytokinesis, but none in control animals. In
summary, activating NRG1/ErbB4 signaling induces quiescent
cardiomyocytes to reenter the cell cycle and to undergo karyoki-
nesis and cytokinesis in vivo.
NRG1-Induced Cell-Cycle Activity In Vivo Stems from
Differentiated Cardiomyocytes
What is the cellular source of NRG1-induced cardiomyocyte cell-
cycle activity? The in vitro optical fate mapping suggested that
NRG1 induces differentiated cardiomyocytes to reenter the cell
cycle. To test this possibility in vivo, we performed a genetic
fate map. Using a-MHC-MerCreMer; Rosa26R mice, we perma-
nently labeled differentiated cardiomyocytes (Figures 4A and
S2C). We then injected NRG1 and quantified BrdU uptake. We
did not detect BrdU-positive cardiomyocytes in the control
group. In NRG1-treated animals, in contrast, we identified
BrdU-positive cardiomyocytes that were X-gal positive, indi-
cating that they were differentiated before they reentered the
cell cycle (Figure 4B). We also found X-gal-positive cardiomyo-
cytes during karyokinesis (Figure 4C). In conclusion, NRG1
induces differentiated cardiomyocytes to reenter the cell cycle.
NRG1 Induces Proliferation of Differentiated
Cardiomyocytes In Vivo
Whether differentiated cardiomyocytes can proliferate is
a controversial question in cardiovascular biology. To answer
this question in vivo, we analyzed the fate of genetically labeled
differentiated cardiomyocytes. We induced sparse genetic
labeling of differentiated cardiomyocytes in a-MHC-Mer-
CreMer+/+; Rosa26R+/ mice (Figure S4). One week later, we
induced cardiomyocyte proliferation by injecting NRG1 for nine
days and quantified the number of multicellular X-gal-positive
clusters of cardiomyocytes. The majority of X-gal-positive cardi-
omyocytes were single (Figures 4D and S4). NRG1-injected
animals (n = 9) had 2.1-fold more clusters of two and 35-fold
more clusters consisting of four and more cardiomyocytes than
did control animals (n = 10; Figure 4E). In conclusion, NRG1
induces proliferation of differentiated cardiomyocytes in vivo.
To determine whether cardiomyocytes can undergo succes-
sive cell divisions in vivo, we labeled with chlorodeoxyuridine
(CldU) for the first 4 days, followed by a 1-day washout period,
and then with iododeoxyuridine (IdU) for the final 4 days of
NRG1 injections (Figure 4F). We readily identified cardiomyo-cytes that were labeled with one thymidine analog, indicating
that they were in the cell cycle once (Figure 4G). We detected
mononucleated cardiomyocytes that took up both thymidine
analogs, signifying that they had gone through S phase,
completed cytokinesis, and cycled again at least once more
(Figure 4H). We also detected binucleated cardiomyocytes that
took up both thymidine analogs (Figure 4I). Quantification of the
frequency of cell-cycle transition in NRG1-stimulated hearts
showed that 0.6% ± 0.2% of cardiomyocytes took up CldU
during the first 4 days, and 0.5% ± 0.1% of cardiomyocytes
took up IdU during the final 4 days of NRG1 stimulation (Fig-
ure 4J). Of note, 50% ± 0.08% of mononucleated cardiomyo-
cytes that went through the cell cycle during the first 4 days
of NRG1 stimulation underwent another round of replication
during the final 4 days (Figure 4J). Of cardiomyocytes that
were double labeled (i.e., that had transitioned two cell cycles),
58% ± 5.9% (n = 117) were mononucleated, indicating that
they completed cytokinesis, consistent with our video micros-
copy data. Because the presence of both thymidine analogs
in a mononucleated cardiomyocyte allowed us to conclude that
they underwent cytokinesis at least once, we can determine
the frequency of cytokinesis, which was 0.15% ± 0.04% of all
cardiomyocytes over a period of 4 days in NRG1-injected
animals, but zero in control animals. In conclusion, NRG1 stimu-
lates a significant portion of mononucleated cardiomyocytes to
replicate.
Cytokinesis is a particular challenge for differentiated cardio-
myocytes because they contain contractile fibrils organized in
sarcomeres. This raises an important question: how do differen-
tiated cardiomyocytes divide their nuclei and cell bodies? To
address this question, we visualized the sarcomeric structure in
dividing cardiomyocytes. During karyokinesis, the sarcomeric
Z-disks and M-bands were disassembled in the region of the
midzone (Figure 4K). Notably, in cytokinesis, the sarcomeric
structure was absent from the division plane (Figure 4L). In
conclusion, cardiomyocyte division is associated with sarcomere
disassembly.
Undifferentiated Progenitor Cells Do Not Contribute
to NRG1-Induced Cardiomyocyte Proliferation
Our results thus far indicate that NRG1 induces differentiated
cardiomyocytes to proliferate. However, generation of cardio-
myocytes from undifferentiated progenitor cells may also contri-
bute to the observed effect. If NRG1-induced cardiomyocyte
proliferation had two different cellular origins—that is, stemmed
from differentiated cardiomyocytes and from undifferentiated
progenitor cells—then there should be detectable differences
between both processes. We labeled differentiated cardiomyo-
cytes genetically by activating the a-MHC-MerCreMer+/+; Ro-
sa26R+/+ system. A hallmark of cardiomyocytes derived from
undifferentiated stem or progenitor cells is that they do not carry(K) Cardiomyocytes in karyokinesis, visualized with an antibody against phosphorylated histone 3B (H3B) begin to disassemble their contractile apparati,
visualized with a Z-disk marker (a-actinin) and an M-band marker (myomesin).
(L) Cardiomyocytes in cytokinesis, visualized with an antibody against aurora B kinase, have complete disassembly of the contractile apparatus, visualized with
antibodies against a Z-disk marker (a-actinin) and an M-band marker (myomesin). Perpendicular reconstructions are indicated with numbered arrowheads. Color
codes are indicated at the top. Statistical significance was determined by ANOVA (E and J). Scale bars 25 mm (B, C, K, and L) and 100 mm (D and G–I). Results are
means ± SEM of at least seven animals per experiment.
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Figure 5. Undifferentiated Progenitor Cells Do Not Contribute to NRG1-Induced Cardiomyocyte Cell-Cycle Activity
(A and B) Examples of X-gal-positive and -negative differentiated cardiomyocytes that had undergone DNA synthesis (A) and mononucleated cardiomyocyte in
the cell cycle (B), which have identical morphology, suggesting similar cellular origins.
(C) Experimental design for dynamic genetic fate map. Differentiated cardiomyocytes were genetically labeled by activation of b-galactosidase transcription,
visualized by X-gal staining. Cardiomyocyte proliferation was induced by injecting NRG1 into adult mice (2 months of age).
(D) Stepwise incremental genetic labeling demonstrates lack of correlation between genetic labeling frequency and NRG1-induced cardiomyocyte generation,
thus indicating that genetically labeled and unlabeled cardiomyocytes originate from differentiated cardiomyocytes.
(E) Regression of NRG1-induced cardiomyocyte generation and recombination frequency shows lack of correlation between genetic labeling frequency and cell-
cycle activity in the genetically unlabeled fraction, indicating that NRG1-induced cardiomyocyte proliferation originates from differentiated cardiomyocytes. Color
codes indicated at the top. Scale bars 50 mm. Statistical significance was determined by ANOVA (D) and by linear regression (E). Results are means ± SEM from
more than 11 animals per experiment.the a-MHC promoter-dependent genetic label (Hsieh et al.,
2007). Thus, genetically labeled cardiomyocytes are derived
from differentiated cardiomyocytes. In contrast, cardiomyocytes
without the genetic label could be derived from differentiated
cardiomyocytes or from undifferentiated progenitor cells. After
applying the genetic label, we induced proliferation with NRG1
and labeled with BrdU to visualize newly generated cardiomyo-
cytes. To determine the contribution of progenitor cells to
NRG1-induced cardiomyocyte proliferation, we compared
BrdU-positive, X-gal-positive (cardiomyocyte-derived) with
BrdU-positive, X-gal-negative cardiomyocytes (possibly progen-
itor cell-derived). The morphology of newly generated X-gal-posi-
tive and X-gal-negative cardiomyocytes was identical (Figure 5A).
We visualized cardiomyocytes that were presently in the cell
cycle with H3P staining and compared X-gal-positive with X-
gal-negative cardiomyocytes, which were identical (Figure 5B).
These results suggested that X-gal-positive and X-gal-negative
BrdU-positive cardiomyocytes had the same cellular origin (i.e.,
they originated from differentiated cardiomyocytes).
Because differentiated cardiomyocytes and undifferentiated
progenitor cells may have different proliferative rates, we
compared the proportion of BrdU-positive cardiomyocytes264 Cell 138, 257–270, July 24, 2009 ª2009 Elsevier Inc.derived from either origin. Cardiomyocytes stemming from differ-
entiated cardiomyocytes are BrdU positive and X-gal positive,
and cardiomyocytes stemming from undifferentiated progenitor
cells are BrdU positive and X-gal negative. We compared the
percentage of BrdU-positive cardiomyocytes across a range of
genetic labeling frequencies (Figures 5C and 5D). We found
that the proliferative rates were identical in X-gal-negative and
X-gal-positive cardiomyocytes at low, intermediate, and high
genetic labeling frequencies, indicating that NRG1-induced
cardiomyocyte proliferation stemmed from a single cellular
source (Figure 5D).
If there was an influx of cardiomyocytes from undifferentiated
progenitor cells, then the measured proliferative rate in this
portion should increase with increasing fraction of X-gal-positive
cardiomyocytes. Thus, we correlated the proliferative rate of
X-gal-negative cardiomyocytes with the genetic labeling fre-
quency (Figure 5E). We found no correlation between the prolif-
erative rate of X-gal-negative cardiomyocytes and the X-gal
labeling frequency, thus excluding the influx of cardiomyocytes
from undifferentiated progenitor cells. In summary, NRG1-
induced cardiomyocyte proliferation has a single source, which
stems from differentiated cardiomyocytes.
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Figure 6. NRG1 Treatment Improves Myocardial Function and Induces Scar Regression
(A) Experimental design. Myocardial infarction was induced at 2 months of age. NRG1 or vehicle injections were begun 1 week later and continued for 1 or for
12 weeks. All mice were treated with BrdU in the drinking water during the final week of injections as indicated by the green arrow. Animals in the 12-week treat-
ment arm were euthanized 2 weeks later to determine whether NRG1 effects were permanent.
(B) NRG1 treatment improves ventricular remodeling and myocardial function as shown by echocardiographic measurements of left ventricular internal dimen-
sions (LVID), interventricular septum (IVS), left ventricular posterior wall (LVPW), and ejection fraction (EF).
(C and D) Infarct scar of representative examples of control and NRG1-treated hearts (C) and quantification (D).
(E) Heart weight is not affected by NRG1 treatment.
(F) Cardiomyocyte cross-sectional area is lower in NRG1-treated hearts. Statistical significance determined by ANOVA (B, D, and E) and t test (F). Scale bars
2 mm (C) and 50 mm (F). Results are means ± SEM from 10–32 animals.NRG1 Improves Cardiac Function and Structure after
Myocardial Infarction
To determine whether inducing cardiomyocyte proliferation with
NRG1 is beneficial after myocardial injury, we permanentlyligated the left anterior descending coronary artery (LAD) in
2-month-old mice and began daily NRG1 injections one week
later for 12 weeks. Because regeneration would be anticipated
to produce a permanent structural change, we introduced aCell 138, 257–270, July 24, 2009 ª2009 Elsevier Inc. 265
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Figure 7. NRG1 Promotes Cardiomyocyte Proliferation after Myocardial Infarction
(A) Quantification of cardiomyocyte DNA synthesis after 1 week of continuous labeling with BrdU. Representative BrdU-positive cardiomyocyte in scar region.
(B) NRG1 treatment does not affect cardiomyocyte apoptosis.
(C) NRG1 treatment does not affect percentage of mono- and multinucleated cardiomyocytes.
(D) Quantification of cardiomyocyte mitoses by visualization of metaphase chromosomes. H3P-positive cardiomyocyte in scar region.
(E) Quantification of cardiomyocyte cytokineses by visualization of the contractile ring.
(F) Quantification of left ventricular cardiomyocyte nuclei shows significant cardiomyocyte replacement after 12 weeks of NRG1 treatment.
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2 week window of no injections before the end of the experiment
(Figure 6A). We determined myocardial structure and function
by serial echocardiography (Figure 6B; Table S5). Over the
course of the 15-week experiment, NRG1-injected animals had
no significant increase of the dimension of the left ventricle,
whereas control animals had significant left ventricular dilatation,
indicating a positive effect of NRG1 on postinfarction remodel-
ing. Injecting NRG1 induced a sustained improvement of
myocardial function, determined by ejection fraction. Compen-
satory hypertrophy, determined by measuring the thickness of
the interventricular septum and the left ventricular free wall,
was significantly attenuated in NRG1-injected animals. In
summary, NRG1 induced sustained improvements after
myocardial infarction.
To analyze at the tissue level how NRG1 improved myocardial
function, we determined the size of the infarct scar (Figure 6C, S5,
and S6). After 1 week of treatment, control and NRG1-treated
hearts had the same scar size; however, after 12 weeks of treat-
ment and 2 additional weeks without treatment, NRG1-injected
animals had a 46% smaller infarct scar (Figure 6D). We then
compared the heart weight, which was identical at the beginning
and 2 weeks after completion of treatment (Figure 6E). The cardi-
omyocyte cross-sectional area, however, was smaller in NRG1-
treated hearts, consistent with attenuation of cardiomyocyte
hypertrophy (Figure 6F). Collectively, these results indicate that
administration of NRG1 for 12 weeks results in permanently
improved myocardial function, smaller infarct scar size, and
attenuated myocardial hypertrophy.
NRG1 Promotes Replacement of Cardiomyocytes
after Myocardial Infarction
What are the underlying cellular mechanisms for the NRG1-
induced improvements? To determine whether the decreased
infarct scar size correlated with cardiomyocyte cell-cycle reentry,
we quantified cardiomyocyte BrdU uptake. NRG1 increased car-
diomyocyte BrdU uptake by 4.4-fold to 0.18% ± 0.03% without
affecting cardiomyocyte apoptosis or changing the percentage
of mono- and binucleated cardiomyocytes (Figures 7A–7C).
Thus, NRG1 increased cardiomyocyte cell-cycle activity after
myocardial infarction.
Can NRG1-induced cardiomyocyte cell-cycle activity account
for the observed improvements? By visualizing cardiomyocytes
in metaphase, we determined that 2,043 cardiomyocytes per
heart were in karyokinesis (Figure 7D). In conjunction with the
duration of karyokinesis of 1.8 ± 0.3 hr, determined by video
microscopy (n = 18), this would result in 2.3 3 106 replaced car-
diomyocyte nuclei over 12 weeks. We also quantified the portion
of cardiomyocytes with a contractile ring (Figure 7E), which, in
conjunction with a duration of cytokinesis of 1.6 ± 0.3 hr
(n = 10), would result in 722,610 new cardiomyocytes in NRG1-
injected animals over 12 weeks. We then quantified cardiomyo-
cyte nuclei directly. NRG1-treated hearts had 1.43106 more car-
diomyocyte nuclei, equivalent to 690,000 more cardiomyocytes
after 12 weeks (Figure 7F). Thus, NRG1-induced cardiomyocyteproliferation can account for the observed cardiomyocyte
replacement.
To determine the cellular source of NRG1-induced cardiomyo-
cyte replacement after injury, we permanently labeled differenti-
ated cardiomyocytes with a genetic tag. We found that cycling
cardiomyocytes that were genetically labeled were identical in
morphology and proliferative rate to unlabeled cardiomyocytes
(Figures 7G and 7H), indicating that undifferentiated stem and
progenitor cells did not contribute to NRG1-induced cardiomyo-
cyte replacement.
Bone marrow-derived c-kit-positive progenitor cells are
required for the endogenous repair process after myocardial
infarction (Fazel et al., 2006). The frequency of c-kit-positive cells
was identical in control and in NRG1-injected animals (Figure S6),
suggesting that NRG1 did not affect recruitment of c-kit-positive
cells.
DISCUSSION
Our study demonstrates that differentiated cardiomyocytes can
be induced to proliferate by activating NRG1/ErbB4 signaling,
leading to enhanced myocardial regeneration and improved
heart function. These findings offer a new strategy to promote
the repair process after myocardial infarction. Several lines of
evidence support this notion. First, we show that NRG1 induces
differentiated cardiomyocytes to divide. Second, we show that
NRG1-induced cardiomyocyte proliferation requires ErbB4.
Third, we demonstrate that mononucleated differentiated cardi-
omyocytes disassemble their sarcomeres during division.
Finally, we show that NRG1-induced cardiomyocyte proliferation
promotes cardiac repair.
Molecular Mechanisms of Cardiomyocyte Proliferation
Stimulation of cell-cycle activity by extracellular NRG1 suggests
that non-cell-autonomous mechanisms control the return of
differentiated cardiomyocytes into a proliferative state. A similar
mechanism operates in differentiated tracheal cells, which are
induced to proliferate by FGF signaling during Drosophila meta-
morphosis (Guha et al., 2008; Weaver and Krasnow, 2008). Our
NRG1/ErbB4 model is the latest addition to a number of molec-
ular strategies used to augment mammalian heart regeneration:
administration of recombinant periostin peptide (Kuhn et al.,
2007) and FGF administration with inhibition of p38 mitogen-
activated kinase (Engel et al., 2006; Engel et al., 2005). Interest-
ingly, all four extracellular factors known to induce proliferation of
differentiated cardiomyocytes (i.e., IGF1, FGF1, periostin, and
NRG1) require PI3-kinase (Figure 7I). It is important to note that
IGF1 and FGFs also induce cardiac hypertrophy, whereas
NRG1 does not. In addition, cell-cycle activators (e.g., simian
virus 40 large T antigen, cyclin A2, and cyclin D2) have been
expressed in cardiomyocytes (Chaudhry et al., 2004; Katz
et al., 1992; Pasumarthi et al., 2005), resulting in increased
cardiomyocyte proliferation. Thus, very specific signals at the
receptor, postreceptor, and at cell-cycle control levels may(G and H) Examples (G) and quantification (H) of X-gal-positive and -negative differentiated mononucleated cardiomyocytes that had undergone DNA synthesis,
which have identical morphology, suggesting similar cellular origins.
(I and J) Molecular (I) and cellular models (J) of cardiomyocyte proliferation. Results are means ± SEM from 11–24 animals.
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induce differentiated cardiomyocytes to reenter the cell cycle.
Periostin (Kuhn et al., 2007) and FGF1 (Engel et al., 2006) were
locally administered, but we applied NRG1 systemically, thus
increasing the translational potential.
Proliferating Cardiomyocytes Have Some
Characteristics of Facultative Stem Cells
Facultative stem cells are in proliferative quiescence during adult
life but return to a proliferative state upon stimulation (Rawlins
and Hogan, 2006). It is formally possible that NRG1 can induce
undifferentiated cardiac progenitor cells to proliferate and
subsequently differentiate into mature cardiomyocytes (Chen
et al., 2007; Hsieh et al., 2007). To exclude this as an explanation
for our experimental results and to demonstrate that NRG1
induces proliferation of differentiated cardiomyocytes, we pro-
vide four lines of evidence: first, we showed with fate-mapping
in vitro and in vivo that NRG1 induces differentiated cardiomyo-
cytes to reenter the cell cycle. Second, we demonstrated that
individual differentiated cardiomyocytes can give rise to multi-
cellular clusters in vivo. Third, using dynamic genetic labeling
in vivo, we demonstrated that NRG1-induced cardiomyocyte
proliferation does not result from undifferentiated stem or
progenitor cells. Fourth, NRG1 does not increase immigration
of circulating c-kit-positive cells. Thus, our results indicate that
NRG1 and ErbB4 control proliferation of a portion of differenti-
ated cardiomyocytes.
Cellular Mechanisms of Cardiomyocyte Proliferation
We determined that, in vitro, NRG1 induces approximately 0.6%
of all differentiated cardiomyocytes to divide over a period of 9
days. This finding is in agreement with approximately 0.15% of
cardiomyocytes dividing over a 4-day period in vivo (Figure 4J)
and 1.7% giving rise to multicellullar clusters over a 9-day period
in vivo (Figure 4E). In comparison, in newts, lower vertebrates
that regenerate their hearts, 29% of cardiomyocytes have prolif-
erative capacity (Bettencourt-Dias et al., 2003). Zebrafish, which
are also capable of cardiac regeneration, have more than 95%
mononucleated cardiomyocytes with proliferative potential
(Wills et al., 2008). Thus, the higher regenerative capacity of adult
newt and zebrafish hearts may be related to the higher preva-
lence of proliferation-competent mononucleated cardiomyo-
cytes in these species (Table S6).
We demonstrated that mononucleated cardiomyocytes have
a higher proliferative potential than do binucleated cardiomyo-
cytes. Mononucleated, but not binucleated, cardiomyocytes
can complete cytokinesis. However, not all mononucleated car-
diomyocytes that perform karyokinesis go on to divide. Approx-
imately 50% of mononucleated cardiomyocytes that reentered
the cell cycle also completed cyctokinesis. The other 50% did
not and became binucleated (Figure 7J). Although the factors
that control whether a mononucleated cardiomyocyte divides
or becomes binucleated are unknown, this mechanism main-
tains the pool of proliferation-competent mononucleated cardio-
myocytes, while generating terminally differentiated binucleated
cardiomyocytes.
That differentiated cardiomyocytes may be capable of reen-
tering the cell cycle has been repeatedly proposed throughout
the past century (Pasumarthi and Field, 2002; Soonpaa and268 Cell 138, 257–270, July 24, 2009 ª2009 Elsevier Inc.Field, 1998). However, it was suggested that the presence of
differentiated sarcomeres is incompatible with cytokinesis
(Ahuja et al., 2007). If cardiomyocytes can divide, they must
possess mechanisms coordinating the cellular changes required
for karyokinesis and cytokinesis with the presence of sarco-
meres. We demonstrated here that differentiated cardiomyo-
cytes disassemble their sarcomeres in the midzone during
karyokinesis and cytokinesis. Thus, our data indicate that the
presence of the differentiated cardiomyocyte contractile appa-
ratus does not prohibit karyokinesis or cytokinesis.
It is tempting to propose that NRG1 induces permanent sarco-
meric dedifferentiation in adult cardiomyocytes, which may
facilitate their proliferation. We did not find evidence for general
cardiomyocyte dedifferentiation in NRG1-injected or ErbB4-
transgenic animals. Furthermore, NRG1 induces differentiation
of embryonic stem cells into cardiomyocytes (Wang et al.,
2008) andNRG1, ErbB2, and ErbB4-deficient mice lack myocar-
dial trabeculations (Gassmann et al., 1995; Lee et al., 1995; Meyer
and Birchmeier, 1995), suggesting that NRG1 and its receptors
may control cardiomyocyte differentiation during development.
We demonstrated here that NRG1 and ErbB4 regulate cardio-
myocyte proliferation during postnatal life, consistent with pleio-
tropic effects of NRG1 that depend on the tissue context.
NRG1-Induced Cardiomyocyte Proliferation Suggests
a New Myocardial Regeneration Strategy
Although control and NRG1-treated hearts had the same heart
weight 15 weeks after myocardial infarction, NRG1-treated
hearts had less hypertrophy at the cardiomyocyte level, as
determined by cross-sectional area. This finding suggests that
sustained cardiomyocyte replacement may have attenuated
the hypertrophic drive after myocardial infarction, resulting in
improved ventricular remodeling. These results are consistent
with improved cardiac function after administration of NRG1 in
a variety of animal models of heart failure (Liu et al., 2006).
Collectively, we have identified the major elements of a new
approach to promote myocardial regeneration. These elements
include identification of an exogenous activator (NRG1) of prolif-
eration of differentiated cardiomyocytes; the receptor mecha-
nism (ErbB4) that, when activated, initiates cardiomyocyte
proliferation; the type of cells (mononucleated) that respond to
activation; and the percentage of these cells that respond.
Many efforts and important advances have been made toward
the goal of developing stem-cell based strategies to regenerate
damaged tissues in the heart as well as in other organs. The work
presented here suggests that stimulating differentiated cardio-
myocytes to proliferate may be a viable alternative that could
be developed into a simple strategy to promote myocardial
regeneration in mammals.
EXPERIMENTAL PROCEDURES
Cell-Cycle Activity In Vitro
Experiments were approved by the Animal Care and Use Committee. Ventric-
ular cardiomyocytes were isolated from male Wistar rats (12 weeks old, 300 g,
Charles River Laboratories; Engel et al., 2005). We added NRG1 (EGF-like
domain, amino acids 176–246; 100 ng/ml, R&D Systems), the peptide consist-
ing of the four fasciclin 1 domains of human periostin (500 ng/ml; BioVendor),
FGF1 (100 ng/ml; R&D Systems), HB-EGF (10 ng/ml; R&D Systems), or
PDGF-BB (10 ng/ml; Peprotech). For detection of DNA synthesis, we added
BrdU (30 mM) for the last three days. The c-ErbB2/Neu blocking antibody
was from Calbiochem.
Mouse Strains, Cardiomyocyte Proliferation, and Genetic Fate
Tracking In Vivo
We provide a detailed description of mouse strains in the Supplemental Exper-
imental Procedures. We used the a-MHC-MerCreMer strain (Sohal et al., 2001)
to delete the loxP-flanked exon 2 of ErbB4 (Golub et al., 2004). We injected
tamoxifen in mice with two alleles of a-MHC-MerCreMer and one (control) or
two (test) ErbB4 alleles with floxed exon 2. Recombination was detected in
83.5% ± 2% of cardiomyocytes (n = 7; Figure S2C). We used heterozygotes
of the a-MHC-ErbB4 transgenic strain to increase ErbB4 expression (Tid-
combe et al., 2003). NRG1 (2.5 mg/mouse dissolved in 0.1% bovine serum
albumin, i.p.) or 0.1% bovine serum albumin were injected daily for 9 days.
To determine the efficiency of recombination, for genetic fate tracking experi-
ments, to analyze clonal proliferation of cardiomyocytes, and to determine the
contribution of stem cells, we crossed the a-MHC-MerCreMer allele into the
Rosa26lacZ strain (Soriano, 1999), injected tamoxifen, and analyzedb-galacto-
sidase-positive and -negative cardiomyocytes. Injections of BrdU (70 mmol/kg,
i.p.), with a tissue half-life of 2 hr, were given every 12 hr. For continuous
labeling, one injection of thymidine analog was given followed by addition to
the drinking water (1 mg/ml) for 9 days (Teta et al., 2007). Cardiomyocytes were
isolated 24 hr later by Langendorff perfusion with collagenase II (20 mg/ml,
Invitrogen) and protease XIV (5 mg/ml, Sigma). Cell-cycle activity and
number of cardiomyocyte nuclei were determined by immunofluorescence
microscopy.
Microscopy, Cardiomyocyte Volumes andCross-Sectional Area, and
Sarcomere Disassembly
Immunofluorescence microscopy and fate tracking in vitro were performed as
described elsewhere (Kuhn et al., 2007). We used primary antibodies against
tropomyosin (Developmental Studies Hybridoma Bank), troponin I (Santa
Cruz), BrdU (Abcam), and aurora B kinase (BD Biosciences) for detection
and Alexa-fluorophore-conjugated secondary antibodies (Invitrogen) for visu-
alization. We visualized nuclei with 40,60-diamidino-phenylindole (DAPI, Invitro-
gen). The g value for image acquisition was set at one. Lookup table settings
were linear (details of image acquisition in Table S7). For live cell imaging, we
maintained cardiomyocytes in an environmental chamber (Tokai-HIT) fitted on
the motorized stage (Prior) of an inverted Olympus IX-81 microscope. We used
adenoviral transduction to express a fusion construct of histone 2B-GFP under
control of the chicken troponin T promoter (cTNT-H2B-GFP; Kuhn et al., 2007).
Movies were acquired with a 203 objective, NA 0.45, by a CCD (Hamamatsu)
at multiple locations in 1-hr intervals. To determine cardiomyocyte dimensions
and volume, we visualized cardiac contractile apparati in isolated cardiomyo-
cytes with an antibody against troponin I (Santa Cruz Biotechnology), acquired
confocal stacks with a step size of 0.5 mm, and analyzed by histomorphometry.
To determine cardiomyocyte cross-sectional area, we stained cryosections
of 14 mm thickness with Masson’s Trichrome and determined the area after
digital thresholding (Metamorph, Molecular Devices). To determine sarcomere
disassembly, we stained cryosections with either a-actinin (Sigma) or myome-
sin (Developmental Studies Hybridoma Bank) antibodies to visualize Z-disk or
M-band, respectively. Karyokinesis was visualized with a phosphorylated
histone H3 antibody (Upstate). Cytokinesis was visualized with an antibody
against aurora B kinase (Sigma). Images were obtained using a spinning-
disk confocal microscope (DSU, Olympus).
Determination of Cardiomyocyte and Stem Cell Contribution
We provide a detailed description of these methods in Supplemental Experi-
mental Procedures. Briefly, to visualize proliferation of individual cardiomyo-
cytes in vivo, we induced sparse genetic labeling in a-MHC-MerCreMer+/+;
Rosa26R+/ mice with tamoxifen (5 mg/gm i.p.3 1), injected NRG1, and quan-
tified clusters of one, two, and more genetically labeled cardiomyocytes on
X-gal-stained sections. To determine the contribution of undifferentiated
stem and progenitor cells, we genetically labeled differentiated cardiomyo-
cytes in a-MHC-MerCreMer+/+; Rosa26R+/ mice. If NRG1-induced cardio-
myocyte cell-cycle activity originated from differentiated cardiomyocytes,the proliferative rate should be identical in genetically labeled and unlabeled
cardiomyocytes, irrespective of the percentage of genetically labeled cardio-
myocytes. In contrast, if the NRG1-induced cardiomyocyte cell-cycle activity
originated from undifferentiated progenitor cells, the proliferative rate should
change with the percentage of genetically labeled cardiomyocytes. We
addressed these possibilities by quantifying the proliferative rate of X-gal-posi-
tive and -negative cardiomyocytes across a range of labeling efficiencies.
Quantification of Myocardial Function and Regeneration
We performed sedated echocardiography using a VisualSonics device with
a 40 MHz probe. To quantify myocardial regeneration, we analyzed 1.53
magnification pictures of AFOG-stained cryosections (Kuhn et al., 2007).
Cardiomyocyte nuclei were counted using the optical dissector method.
Cardiomyocyte apoptosis was determined using the ApopTag Red In Situ
apoptosis detection kit (Chemicon).
Statistical Analyses
Investigators (K.B., S.A., B.H., and B.K.) quantified observations indepen-
dently from one another and in a blinded manner (details in Table S8). Numeric
data are presented as mean ± standard error of the mean (SEM). We tested
statistical significance with the t-test and analysis of variance (ANOVA). We
used sigmoidal nonlinear or linear regression to fit data (GraphPad). The
a-value was set at 0.05.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, seven
figures, eight tables, and two movies and can be found with this article online
at http://www.cell.com/supplemental/S0092-8674(09)00522-4.
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